11 stocks that pass Warren Buffett's capital efficiency test

Warren Buffett has long championed the power of businesses that generate high and consistent return on equity (ROE), demonstrating solid capital discipline. For Buffett, a company's ability to deploy capital efficiently without unnecessary leverage is a key indicator of its long-term potential. Hence, we set out to find companies that fit the bill.

We used three filters:

• 10-year average ROE above 20 per cent
  
• At least 15 per cent ROE in every year over the last decade
  
• Annual diluted earnings per share (EPS) growth of over 20 per cent over FY19-24

This combination of steady returns and earnings momentum ensured we filter out short-term performers and find long-term compounders that have built intrinsic value year after year. 15 stocks made the cut. We have listed 11 in the table that are four/five-star rated in our Stock Ratings.

Below is a brief analysis of two standout names from our list: Kovai Medical Center and Hospital and Mankind Pharma .

Kovai Medical Center and Hospital

Kovai Medical Center, based in Coimbatore, is one of Southern India's leading multi-specialty hospital chains. Over the years, it has strategically expanded into high-value specialties like oncology and cardiology, two areas with both strong demand and the ability to command higher prices. This focus on high-margin services has been a key driver of sustained profitability.

Kovai's ROE of 22.9 per cent over the last decade reflects its disciplined approach to capital allocation and operational efficiency. Unlike many hospitals that rely heavily on external doctors, Kovai maintains a leaner, more efficient model by having a core team of in-house specialists, partly recruited from its medical college. This reduces reliance on costly external consultants, a factor that supports consistent margins.

Its medical college generated Rs 63 crore in the first nine months of FY24, about 7 to 8 per cent of overall revenue. The education segment also benefits from high margins and low cyclicality, further supporting earnings quality. The company's clean balance sheet with minimal debt is another hallmark. Its capital expenditure of Rs 61 crore in FY24 was funded entirely through internal accruals.

But despite these strengths, Kovai's regional focus limits its growth potential. The company is primarily concentrated in Coimbatore and while its local market share is strong, its lack of national expansion remains a key concern. Further regional concentration risks like local regulatory changes or market saturation could potentially affect its long-term growth prospects. Considering this, the company's current P/E of around 29 times, significantly above its five-year median of 19 times, warrants caution.

Mankind Pharma

Mankind Pharma is among the most efficiently run pharma businesses in the domestic market. Unlike many of its peers, Mankind has focused primarily on India's underpenetrated rural and semi-urban markets, where it has built a dominant presence in branded generics and consumer healthcare.

Mankind's strategy is rooted in its distribution-led model, which is supported by aggressive doctor engagement and mass-market affordability. This approach has allowed the company to scale quickly without significantly inflating its costs. Operational leverage from rising volumes and disciplined cost control has supported robust profit growth, with its diluted EPS compounding by 27 per cent over FY19-24.

The company also focuses on chronic therapies like cardiac and diabetes, areas with strong long-term demand. Meanwhile, its consumer healthcare business, which includes well-known brands like Manforce, Prega News and Gas-O-Fast, adds diversification and pricing power, further strengthening its margin profile.

Post-IPO, Mankind significantly reduced its debt, fortifying its balance sheet and setting the stage for future growth. While its focus has been primarily domestic, it is now exploring selective export opportunities, particularly in high-margin therapeutic areas, which could provide the next leg of growth.

However, Mankind faces risks. Its overdependence on the Indian market exposes it to potential domestic regulatory changes, including price controls and shifting norms around medical marketing. Additionally, its low R&D spend could limit its ability to build a more differentiated pipeline, especially as it eyes global markets. In view of these risks, the company's current valuation of around 51 times appears inflated.

Before you leave

The above filters can help you spot companies that consistently deliver high ROE and demonstrate disciplined capital allocation, key qualities that align with Buffett's investment philosophy. These businesses stand out for their ability to perform reliably across various market cycles, making them worthy of further attention. However, they are not our recommendations. It's important to remember that stock screens or filters are only a starting point, not the final decision. A deeper understanding of each company's business model, financial health, and growth prospects is essential before committing to any investment.

For thoroughly researched stock ideas, you can explore Value Research Stock Advisor for our carefully vetted stock recommendations.

Also read: 9 hidden gems Peter Lynch would pick today